Marker Therapeutics, Inc.
MRKR
$0.88
-$0.04-3.95%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -26.34% | -71.94% | 113.14% | 647.67% | 53.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.34% | -71.94% | 113.14% | 647.67% | 53.30% |
| Cost of Revenue | 78.86% | 21.76% | 94.33% | 69.74% | -1.79% |
| Gross Profit | -184.33% | -109.34% | -81.60% | 13.55% | 27.80% |
| SG&A Expenses | -17.23% | 12.40% | -25.42% | -39.50% | -54.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.30% | 18.76% | 53.05% | 25.11% | -28.99% |
| Operating Income | -84.61% | -63.02% | -31.44% | 25.00% | 44.17% |
| Income Before Tax | -83.13% | -85.82% | -38.41% | 22.60% | 46.51% |
| Income Tax Expenses | -- | -- | 1,251.35% | -- | -- |
| Earnings from Continuing Operations | -83.13% | -85.82% | -40.05% | 22.60% | 46.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -83.13% | -85.82% | -36.91% | 22.60% | -187.16% |
| EBIT | -84.61% | -63.02% | -31.44% | 25.00% | 44.17% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -17.00% | -48.92% | -32.64% | 23.44% | -186.01% |
| Normalized Basic EPS | -16.98% | -33.75% | -34.04% | 23.44% | 47.22% |
| EPS Diluted | -16.00% | -48.92% | -32.64% | 23.53% | -188.72% |
| Normalized Diluted EPS | -16.98% | -33.75% | -34.04% | 23.44% | 47.22% |
| Average Basic Shares Outstanding | 56.50% | 24.76% | 3.23% | 1.10% | 1.35% |
| Average Diluted Shares Outstanding | 56.50% | 24.76% | 3.23% | 1.10% | 1.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |